Amgen Begin Period Cash Flow vs End Period Cash Flow Analysis

AMGN Stock

USD 275.75 1.88 0.68%

Amgen financial indicator trend analysis is way more than just evaluating Amgen Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amgen Inc is a good investment. Please check the relationship between Amgen Begin Period Cash Flow and its End Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Begin Period Cash Flow vs End Period Cash Flow

Begin Period Cash Flow vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amgen Inc Begin Period Cash Flow account and End Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Amgen's Begin Period Cash Flow and End Period Cash Flow is 0.75. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Amgen Inc, assuming nothing else is changed. The correlation between historical values of Amgen's Begin Period Cash Flow and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Amgen Inc are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Begin Period Cash Flow i.e., Amgen's Begin Period Cash Flow and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.75

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

End Period Cash Flow

Most indicators from Amgen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amgen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

At this time, Amgen's Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Tax Provision is likely to grow to about 1.4 B, while Enterprise Value Over EBITDA is likely to drop 13.42.

	2021	2022	2023	2024 (projected)
Interest Expense	1.2B	1.4B	2.9B	3.0B
Depreciation And Amortization	3.4B	3.3B	4.1B	4.3B

Interest Expense Depreciation And Amortization

Amgen fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Inventory	Accounts Payable	Common Stock Total Equity	Short Term Investments	Capital Stock
Total Assets		0.93	0.76	0.81	0.33	0.67	0.94	-0.4	0.67	0.86	0.62	0.35	0.78	-0.49	0.92	-0.11	0.47	0.91	0.63	0.52	0.27	0.76	0.81	0.79	0.37	0.77
Short Long Term Debt Total	0.93		0.9	0.91	-0.01	0.52	0.99	-0.61	0.83	0.95	0.83	0.02	0.94	-0.55	0.99	-0.14	0.72	0.99	0.81	0.21	0.13	0.95	0.82	0.64	0.08	0.6
Other Current Liab	0.76	0.9		0.97	-0.33	0.48	0.85	-0.87	0.94	0.93	0.93	-0.25	0.98	-0.75	0.93	-0.1	0.81	0.95	0.89	-0.02	0.0	0.92	0.91	0.62	-0.25	0.58
Total Current Liabilities	0.81	0.91	0.97		-0.23	0.51	0.88	-0.81	0.87	0.9	0.83	-0.12	0.94	-0.76	0.92	-0.2	0.73	0.95	0.82	0.1	0.26	0.88	0.89	0.67	-0.12	0.63
Total Stockholder Equity	0.33	-0.01	-0.33	-0.23		0.34	0.07	0.66	-0.35	-0.12	-0.45	0.88	-0.29	0.37	-0.05	0.14	-0.51	-0.09	-0.36	0.79	0.34	-0.27	-0.11	0.31	0.88	0.36
Property Plant And Equipment Net	0.67	0.52	0.48	0.51	0.34		0.51	-0.35	0.46	0.51	0.28	0.37	0.45	-0.56	0.52	0.21	0.16	0.53	0.39	0.62	0.27	0.36	0.61	0.96	0.25	0.94
Net Debt	0.94	0.99	0.85	0.88	0.07	0.51		-0.53	0.76	0.93	0.78	0.09	0.89	-0.51	0.98	-0.21	0.68	0.97	0.76	0.27	0.17	0.92	0.8	0.63	0.16	0.59
Retained Earnings	-0.4	-0.61	-0.87	-0.81	0.66	-0.35	-0.53		-0.85	-0.71	-0.82	0.56	-0.82	0.79	-0.66	0.07	-0.74	-0.7	-0.79	0.33	0.09	-0.72	-0.76	-0.46	0.62	-0.43
Cash	0.67	0.83	0.94	0.87	-0.35	0.46	0.76	-0.85		0.85	0.88	-0.31	0.94	-0.58	0.85	0.18	0.79	0.87	0.87	-0.1	-0.09	0.89	0.77	0.56	-0.32	0.51
Non Current Assets Total	0.86	0.95	0.93	0.9	-0.12	0.51	0.93	-0.71	0.85		0.88	-0.18	0.95	-0.65	0.96	-0.16	0.74	0.96	0.83	0.04	0.02	0.94	0.85	0.65	-0.14	0.61
Non Currrent Assets Other	0.62	0.83	0.93	0.83	-0.45	0.28	0.78	-0.82	0.88	0.88		-0.44	0.94	-0.63	0.85	-0.12	0.9	0.86	0.91	-0.24	-0.27	0.92	0.75	0.41	-0.4	0.35
Cash And Short Term Investments	0.35	0.02	-0.25	-0.12	0.88	0.37	0.09	0.56	-0.31	-0.18	-0.44		-0.26	0.21	0.0	0.05	-0.48	-0.03	-0.34	0.94	0.48	-0.28	-0.01	0.35	0.97	0.39
Net Receivables	0.78	0.94	0.98	0.94	-0.29	0.45	0.89	-0.82	0.94	0.95	0.94	-0.26		-0.65	0.95	-0.06	0.84	0.96	0.91	-0.04	-0.03	0.97	0.84	0.58	-0.23	0.53
Common Stock Shares Outstanding	-0.49	-0.55	-0.75	-0.76	0.37	-0.56	-0.51	0.79	-0.58	-0.65	-0.63	0.21	-0.65		-0.61	0.38	-0.5	-0.65	-0.6	-0.07	-0.16	-0.51	-0.81	-0.68	0.31	-0.65
Non Current Liabilities Total	0.92	0.99	0.93	0.92	-0.05	0.52	0.98	-0.66	0.85	0.96	0.85	0.0	0.95	-0.61		-0.16	0.72	1.0	0.81	0.2	0.08	0.93	0.88	0.67	0.04	0.62
Other Current Assets	-0.11	-0.14	-0.1	-0.2	0.14	0.21	-0.21	0.07	0.18	-0.16	-0.12	0.05	-0.06	0.38	-0.16		-0.1	-0.17	-0.04	0.03	-0.29	-0.08	-0.22	0.05	-0.03	0.06
Other Stockholder Equity	0.47	0.72	0.81	0.73	-0.51	0.16	0.68	-0.74	0.79	0.74	0.9	-0.48	0.84	-0.5	0.72	-0.1		0.73	0.96	-0.31	-0.24	0.84	0.59	0.24	-0.42	0.18
Total Liab	0.91	0.99	0.95	0.95	-0.09	0.53	0.97	-0.7	0.87	0.96	0.86	-0.03	0.96	-0.65	1.0	-0.17	0.73		0.83	0.18	0.12	0.93	0.89	0.68	0.01	0.63
Property Plant And Equipment Gross	0.63	0.81	0.89	0.82	-0.36	0.39	0.76	-0.79	0.87	0.83	0.91	-0.34	0.91	-0.6	0.81	-0.04	0.96	0.83		-0.13	-0.15	0.87	0.73	0.47	-0.32	0.43
Total Current Assets	0.52	0.21	-0.02	0.1	0.79	0.62	0.27	0.33	-0.1	0.04	-0.24	0.94	-0.04	-0.07	0.2	0.03	-0.31	0.18	-0.13		0.5	-0.09	0.22	0.6	0.89	0.61
Short Term Debt	0.27	0.13	0.0	0.26	0.34	0.27	0.17	0.09	-0.09	0.02	-0.27	0.48	-0.03	-0.16	0.08	-0.29	-0.24	0.12	-0.15	0.5		-0.06	0.07	0.32	0.45	0.34
Inventory	0.76	0.95	0.92	0.88	-0.27	0.36	0.92	-0.72	0.89	0.94	0.92	-0.28	0.97	-0.51	0.93	-0.08	0.84	0.93	0.87	-0.09	-0.06		0.74	0.47	-0.19	0.4
Accounts Payable	0.81	0.82	0.91	0.89	-0.11	0.61	0.8	-0.76	0.77	0.85	0.75	-0.01	0.84	-0.81	0.88	-0.22	0.59	0.89	0.73	0.22	0.07	0.74		0.77	-0.05	0.76
Common Stock Total Equity	0.79	0.64	0.62	0.67	0.31	0.96	0.63	-0.46	0.56	0.65	0.41	0.35	0.58	-0.68	0.67	0.05	0.24	0.68	0.47	0.6	0.32	0.47	0.77		0.24	0.99
Short Term Investments	0.37	0.08	-0.25	-0.12	0.88	0.25	0.16	0.62	-0.32	-0.14	-0.4	0.97	-0.23	0.31	0.04	-0.03	-0.42	0.01	-0.32	0.89	0.45	-0.19	-0.05	0.24		0.26
Capital Stock	0.77	0.6	0.58	0.63	0.36	0.94	0.59	-0.43	0.51	0.61	0.35	0.39	0.53	-0.65	0.62	0.06	0.18	0.63	0.43	0.61	0.34	0.4	0.76	0.99	0.26

Click cells to compare fundamentals

Amgen Account Relationship Matchups

Amgen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	59.7B	62.9B	61.2B	65.1B	97.2B	102.0B
Short Long Term Debt Total	29.9B	33.0B	33.3B	38.9B	64.6B	67.8B
Other Current Liab	8.5B	9.2B	9.9B	11.2B	13.7B	14.4B
Total Current Liabilities	12.8B	11.7B	12.2B	15.7B	18.4B	19.3B
Total Stockholder Equity	9.7B	9.4B	6.7B	3.7B	6.2B	12.3B
Property Plant And Equipment Net	4.9B	4.9B	5.2B	5.4B	6.6B	3.6B
Net Debt	23.9B	26.7B	25.3B	31.3B	53.7B	56.4B
Retained Earnings	(21.3B)	(21.4B)	(24.6B)	(28.6B)	(26.5B)	(25.2B)
Cash	6.0B	6.3B	8.0B	7.6B	10.9B	11.5B
Non Current Assets Total	41.3B	41.8B	41.8B	42.9B	66.8B	70.2B
Non Currrent Assets Other	2.2B	5.6B	6.5B	5.9B	9.0B	9.4B
Cash And Short Term Investments	8.9B	10.6B	8.0B	9.3B	10.9B	10.5B
Net Receivables	4.1B	4.5B	4.9B	5.6B	7.9B	8.3B
Common Stock Shares Outstanding	609M	590M	573M	541M	538M	759.2M
Liabilities And Stockholders Equity	59.7B	62.9B	61.2B	65.1B	97.2B	102.0B
Non Current Liabilities Total	37.2B	41.9B	42.3B	45.8B	72.5B	76.2B
Other Current Assets	1.9B	2.1B	2.4B	2.4B	1.9B	2.7B
Other Stockholder Equity	(528M)	(985M)	18.2B	21.7B	25.0B	26.2B
Total Liab	50.0B	53.5B	54.5B	61.5B	90.9B	95.5B
Property Plant And Equipment Gross	4.9B	4.9B	14.0B	14.7B	15.7B	16.5B
Total Current Assets	18.4B	21.1B	19.4B	22.2B	30.3B	15.2B
Accumulated Other Comprehensive Income	(528M)	(985M)	(796M)	(231M)	(289M)	(274.6M)
Short Term Debt	3.0B	244M	232M	1.7B	1.4B	1.0B
Inventory	3.6B	3.9B	4.1B	4.9B	9.5B	10.0B
Accounts Payable	1.4B	1.4B	1.4B	1.6B	1.6B	1.7B
Common Stock Total Equity	31.5B	31.8B	32.1B	32.5B	37.4B	27.1B
Short Term Investments	2.9B	4.4B	48M	1.7B	10.9B	12.2B
Capital Stock	31.5B	31.8B	32.1B	32.5B	33.1B	27.5B
Common Stock	31.5B	31.8B	32.1B	32.5B	33.1B	27.5B
Other Assets	955M	1.3B	6.5B	2.2B	2.5B	1.4B
Long Term Debt	27.0B	32.9B	33.2B	37.4B	63.2B	66.3B
Property Plant Equipment	4.9B	4.9B	5.2B	5.4B	6.2B	5.3B
Good Will	14.7B	14.7B	14.9B	15.5B	18.6B	14.4B
Intangible Assets	19.4B	16.6B	15.2B	16.1B	32.6B	34.3B
Other Liab	9.9B	9.0B	9.1B	7.9B	9.1B	5.1B
Net Tangible Assets	(24.4B)	(21.9B)	(23.4B)	(27.9B)	(25.2B)	(23.9B)
Retained Earnings Total Equity	(21.3B)	(21.4B)	(24.6B)	(28.6B)	(25.8B)	(24.5B)
Long Term Debt Total	27.0B	32.9B	33.2B	37.4B	43.0B	29.9B
Non Current Liabilities Other	9.6B	9.0B	2.5B	2.7B	2.3B	2.2B

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amgen Stock

0.9	VALN	Valneva SE ADR	Pair Corr
0.9	ERNA	Eterna Therapeutics	Pair Corr

Moving against Amgen Stock

0.85	BMY	Bristol Myers Squibb	Pair Corr
0.82	ESPR	Esperion Therapeutics	Pair Corr
0.68	DYAI	Dyadic International	Pair Corr
0.6	GILD	Gilead Sciences	Pair Corr
0.41	DNA	Ginkgo Bioworks Holdings	Pair Corr

The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.

The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:

How To Invest In Amgen

Details

Is Amgen Stock a good investment?

Details

What is Amgen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.621

Dividend Share

8.88

Earnings Share

7.83

Revenue Per Share

60.641

Quarterly Revenue Growth

0.232

The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amgen Begin Period Cash Flow vs End Period Cash Flow Analysis

Begin Period Cash Flow vs End Period Cash Flow

Begin Period Cash Flow vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

End Period Cash Flow

Amgen fundamental ratios Correlations

Amgen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amgen fundamental ratios Accounts

Pair Trading with Amgen

Moving together with Amgen Stock

Moving against Amgen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Net Debt	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total
Capital Stock	+ 0.99	Common Stock Total Equity
Net Receivables	+ 0.98	Other Current Liab

Retained Earnings	- 0.87	Other Current Liab
Cash	- 0.85	Retained Earnings
Net Receivables	- 0.82	Retained Earnings
Non Currrent Assets Other	- 0.82	Retained Earnings
Accounts Payable	- 0.81	Common Stock Shares Outstanding
Retained Earnings	- 0.81	Total Current Liabilities